Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

13.59
+1.199.60%
Pre-market: 13.950.3600+2.65%04:39 EDT
Volume:5.38M
Turnover:72.82M
Market Cap:1.21B
PE:-4.04
High:13.90
Open:13.59
Low:12.85
Close:12.40
52wk High:13.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:1.79
T/O Rate:7.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:24.91
PE(LYR):-4.28

Loading ...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 05

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

Lake Street Initiates a Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Jun 05

Kura Oncology Shareholders Approve Expanded Equity Incentive Plans

TIPRANKS
·
Jun 05

Kura Oncology expands 2014 equity incentive plan share reserve to 41,077,686 shares

Reuters
·
Jun 05

Wedbush Sticks to Its Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Jun 04

Kura Oncology releases ASCO 2026 darlifarnib clinical update presentation

Reuters
·
Jun 04

Kura Oncology Plans Wider Platform Study for Darlifarnib Amid Recent Data on Anti-Tumor Activity

MT Newswires Live
·
Jun 03

Kura Oncology plans Phase 1a platform study pairing darlifarnib with daraxonrasib in KRAS-mutant pancreatic cancer

Reuters
·
Jun 03

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

GlobeNewswire
·
Jun 03

Kura Oncology says Blood paper shows 87% response rate for ziftomenib plus venetoclax/azacitidine in relapsed NPM1-mutated AML

Reuters
·
Jun 02

H.C. Wainwright Sticks to Their Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacific Edge Limited (OtherPFGTF), Kura Oncology (KURA) and Eli Lilly & Co (LLY)

TIPRANKS
·
May 27

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), Kura Oncology (KURA) and 3SBio (OtherTRSBF)

TIPRANKS
·
May 26

Kura Oncology Reports Tumor Shrinkage in 77% of Patients in KRAS Cancer Drug Combo Trial

MT Newswires Live
·
May 26

Kura Oncology reports 67% response rate in Phase 1 darlifarnib-adagrasib trial for KRAS G12C pancreatic cancer

Reuters
·
May 26

Kura Oncology Reports Strong Clinical Activity and Safety With Darlifarnib + Adagrasib in Kras G12c-Mutated Solid Tumors

THOMSON REUTERS
·
May 26

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

GlobeNewswire
·
May 26

Kura Oncology Chief Commercial Officer Brian Powl sells 10,000 shares for $110,000

Reuters
·
May 23

Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
May 21